Melanoma Research Victoria
melanoma-mrv.bsky.social
Melanoma Research Victoria
@melanoma-mrv.bsky.social
Melanoma Research Victoria (MRV) is a clinical cohort and research resource committed to improving outcomes for melanoma patients. (melanomaresearchvic.com.au)
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors: Immunity www.cell.com/immunity/ful...
Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors
Cancers initially responsive to immune checkpoint inhibitors (ICIs) often relapse, and localized cancers can recur after surgery plus adjuvant ICI therapy. Wu et al. find that relapsing and recurrent ...
www.cell.com
January 12, 2026 at 1:42 AM
Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma: Immunity www.cell.com/immunity/ful...
Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma
The gut microbiome impacts immunity at various levels, including response to immunotherapy. Bachem et al. find that metabolic pathways shared across different microbiota constituents, including SCFA s...
www.cell.com
January 12, 2026 at 12:30 AM
Association of autoimmune disease with melanoma and nonmelanoma skin cancers url: academic.oup.com/ced/article-...
Association of autoimmune disease with melanoma and nonmelanoma skin cancers
We investigated the association between autoimmune diseases and melanoma/nonmelanoma skin cancers using the All of Us Research Program, a US National Insti
academic.oup.com
January 11, 2026 at 11:30 PM
journals.lww.com
January 9, 2026 at 5:02 AM
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial url: academic.oup.com/bjd/article/...
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial
Patients with BRAF wildtype metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICIs) have limited treatment options. The m
academic.oup.com
January 9, 2026 at 4:59 AM
Compression causes cancer cells to start spreading www.nature.com/articles/d41...
Client Challenge
www.nature.com
January 9, 2026 at 4:56 AM
Hutchinson’s Sign in Subungual Melanoma In Situ | New England Journal of Medicine www.nejm.org/doi/full/10....
Hutchinson’s Sign in Subungual Melanoma In Situ | NEJM
A 71-year-old man presented with a 2-year history of a darkening line on his left thumbnail. Also noted were a brown discoloration of the left thumbnail and hyperpigmentation of the proximal nail f...
www.nejm.org
January 9, 2026 at 4:54 AM
Season's Greeting to all.
December 23, 2025 at 4:01 AM